(Q40052920)

English

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

scientific article published on 9 June 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 September 2017

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study (English)

1 reference

Europe PubMed Central

16 September 2017

0 references

multicenter clinical trial

0 references

0 references

Orthoebolavirus zairense

0 references

object named as

Eric A Sheldon

10

0 references

Thomas P. Monath

12

object named as

Thomas P Monath

1 reference

Europe PubMed Central

16 September 2017

D. Gray Heppner

1

object named as

D Gray Heppner

1 reference

Europe PubMed Central

16 September 2017

author name string

Tracy L Kemp

2

1 reference

Europe PubMed Central

16 September 2017

Brian K Martin

3

1 reference

Europe PubMed Central

16 September 2017

William J Ramsey

4

1 reference

Europe PubMed Central

16 September 2017

Richard Nichols

5

1 reference

Europe PubMed Central

16 September 2017

Emily J Dasen

6

1 reference

Europe PubMed Central

16 September 2017

Charles J Link

7

1 reference

Europe PubMed Central

16 September 2017

Rituparna Das

8

1 reference

Europe PubMed Central

16 September 2017

Zhi Jin Xu

9

1 reference

Europe PubMed Central

16 September 2017

Teresa A Nowak

11

1 reference

Europe PubMed Central

16 September 2017

V920-004 study team

13

1 reference

Europe PubMed Central

16 September 2017

publication date

9 June 2017

1 reference

Europe PubMed Central

16 September 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

16 September 2017

17

1 reference

Europe PubMed Central

16 September 2017

8

1 reference

Europe PubMed Central

16 September 2017

854-866

1 reference

Europe PubMed Central

16 September 2017

The cost of Ebola

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ebola virus vaccines: an overview of current approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

On closed test procedures for dose-response analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of platform technologies for assaying antibody to Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930313-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(17)30313-4

1 reference

Europe PubMed Central

16 September 2017

1 reference

Europe PubMed Central

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40052920&oldid=1883321395"